

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Innate Immunotherapeutics Limited
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Carl Collins
Date of last notice	19 December 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	24 September 2017
No. of securities held prior to change	37,899,139 Fully Paid Ordinary Shares 1,250,000 Options – Exercise Price US\$0.40 & Expiry Date 24 September 2017 2,250,000 Options – Exercise Price US\$0.40 & Expiry Date 5 November 2018 625,000 Options – Exercise Price US\$0.40 & Expiry Date 1 May 2018
Class	Exercise Price US\$0.40 & Expiry Date 24 September 2017
Number acquired	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	1,250,000 – Options Lapsed – not exercised
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	37,899,139 Fully Paid Ordinary Shares 2,250,000 Options – Exercise Price US\$0.40 & Expiry Date 5 November 2018 625,000 Options – Exercise Price US\$0.40 & Expiry Date 1 May 2018
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options Lapsed – not exercised

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

26 September 2017.

⁺ See chapter 19 for defined terms.